Survival analysis of adjuvant endocrine therapy in HER2 positive early breast cancer patients with low ER positivity
{{output}}
Background: Optimal treatment strategies for early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer with low estrogen receptor (ER) expression (1–9%) remain unclear. While endocrine therapy (ET) is st... ...
